The importance of resistance to direct antiviral drugs in HCV infection in clinical practice

C Sarrazin - Journal of hepatology, 2016 - Elsevier
Treatment of chronic hepatitis C virus (HCV) infection with direct-acting antiviral agents
(DAA) is associated with high rates of sustained virologic response. Remaining factors …

Viral quasispecies evolution

E Domingo, J Sheldon, C Perales - Microbiology and Molecular …, 2012 - Am Soc Microbiol
Evolution of RNA viruses occurs through disequilibria of collections of closely related mutant
spectra or mutant clouds termed viral quasispecies. Here we review the origin of the …

Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir

Y Hu, EM Lewandowski, H Tan, X Zhang… - ACS Central …, 2023 - ACS Publications
The SARS-CoV-2 main protease (Mpro) is the drug target of Pfizer's oral drug nirmatrelvir.
The emergence of SARS-CoV-2 variants with mutations in Mpro raised the alarm of potential …

NACSELD acute‐on‐chronic liver failure (NACSELD‐ACLF) score predicts 30‐day survival in hospitalized patients with cirrhosis

JG O'leary, KR Reddy, G Garcia‐Tsao, SW Biggins… - Hepatology, 2018 - journals.lww.com
Several highly effective, interferon‐free, direct‐acting antiviral (DAA)‐based regimens are
available for the treatment of chronic hepatitis C virus (HCV) infection. Despite impressive …

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C

EJ Gane, CA Stedman, RH Hyland… - … England Journal of …, 2013 - Mass Medical Soc
Background The standard treatment for hepatitis C virus (HCV) infection is interferon, which
is administered subcutaneously and can have troublesome side effects. We evaluated …

Ten years of dengue drug discovery: progress and prospects

SP Lim, QY Wang, CG Noble, YL Chen, H Dong, B Zou… - Antiviral research, 2013 - Elsevier
To combat neglected diseases, the Novartis Institute of Tropical Diseases (NITD) was
founded in 2002 through private–public funding from Novartis and the Singapore Economic …

Resistance to direct antiviral agents in patients with hepatitis C virus infection

C Sarrazin, S Zeuzem - Gastroenterology, 2010 - Elsevier
Chronic hepatitis C virus (HCV) infection is one of the major causes of cirrhosis,
hepatocellular carcinoma, and liver failure that leads to transplantation. The current standard …

[HTML][HTML] KASL clinical practice guidelines: management of hepatitis C

Korean Association for the Study of the … - Clinical and …, 2016 - ncbi.nlm.nih.gov
Aims The Korean Association for the Study of the Liver (KASL) Practice Guidelines for
Management of Hepatitis C were first established in 2004, and revised in 2013, when direct …

Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase

MJ Sofia, W Chang, PA Furman… - Journal of medicinal …, 2012 - ACS Publications
Hepatitis C virus (HCV) infection is a global health problem that impacts approximately 180
million individuals. Of those initially infected with HCV approximately 80% will progress to …

Rapid emergence of protease inhibitor resistance in hepatitis C virus

L Rong, H Dahari, RM Ribeiro… - Science translational …, 2010 - science.org
About 170 million people worldwide are infected with hepatitis C virus (HCV). The current
standard therapy leads to sustained viral elimination in only~ 50% of the treated patients …